Development
Novartis AG
NVS
$117.68
$0.840.72%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 8.48B | 1.76B | 2.32B | 2.29B | 1.47B |
| Total Depreciation and Amortization | 1.15B | 1.32B | 1.18B | 1.49B | 1.28B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.69B | 730.00M | -40.00M | 1.38B | 1.24B |
| Change in Net Operating Assets | -737.00M | 923.00M | 119.00M | -2.21B | 133.00M |
| Cash from Operations | 3.20B | 4.73B | 3.58B | 2.96B | 4.11B |
| Capital Expenditure | -406.00M | -261.00M | -156.00M | -237.00M | -306.00M |
| Sale of Property, Plant, and Equipment | 164.00M | 51.00M | -10.00M | 32.00M | 102.00M |
| Cash Acquisitions | -6.00M | -3.45B | -84.00M | -26.00M | -2.00M |
| Divestitures | -2.00M | 2.00M | 16.00M | -13.00M | -5.00M |
| Other Investing Activities | -1.51B | 1.44B | -819.00M | 10.87B | -1.26B |
| Cash from Investing | -1.76B | -2.21B | -1.05B | 10.62B | -1.47B |
| Total Debt Issued | 546.00M | -- | -- | 1.02B | -1.20B |
| Total Debt Repaid | 64.00M | -2.70B | 234.00M | -75.00M | -64.00M |
| Issuance of Common Stock | -- | -- | -1.00M | 159.00M | 0.00 |
| Repurchase of Common Stock | -1.26B | -1.63B | -2.96B | -2.89B | -2.68B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.00 | -- | 0.00 | -7.26B | 0.00 |
| Other Financing Activities | 39.00M | 3.50B | 111.00M | -169.00M | -56.00M |
| Cash from Financing | -607.00M | -832.00M | -3.64B | -9.20B | -3.99B |
| Foreign Exchange rate Adjustments | 160.00M | -166.00M | -1.00M | 107.00M | 141.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 988.00M | 1.52B | -1.12B | 4.48B | -1.21B |